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Abstract
Background: Staphylococcus aureus causes a variety of severe infections such as bacteremia and sepsis. At present, 60–80%
of S. aureus isolates from Taiwan are methicillin resistant (MRSA). It has been shown that certain MRSA clones circulate
worldwide. The goals of this study were to identify MRSA clones in Taiwan and to correlate the molecular types of isolates
with their phenotypes.
Methods: A total of 157 MRSA isolates from bacteremic patients were collected from nine medical centers. They were typed
based on polymorphisms in agr, SCCmec, MLST, spa, and dru. Phenotypes characterized included Panton-Valentine
leucocidin (pvl), inducible macrolide-lincosamide-streptogramin B resistance (MLSBi), vancomycin (VA) and daptomycin
(DAP) minimal inhibitory concentrations (MIC), and superantigenic toxin gene profiles. Difference between two consecutive
samples was determined by Mann-Whitney-U test, and difference between two categorical variables was determined by
Fisher’s exact test.
Results: Four major MRSA clone complexes CC1, CC5, CC8, and CC59 were found, including 4 CC1, 9 CC5, 111 CC8, and 28
CC59 isolates. These clones had the following molecular types: CC1: SCCmecIV and ST573; CC5: SCCmecII and ST5; CC8:
SCCmecIII, ST239, and ST241, and CC59: SCCmecIV, SCCmecVT, ST59, and ST338. The toxin gene profiles of these clones were
CC1: sec-seg-(sei)-sell-selm-(seln)-selo; CC5: sec-seg-sei-sell-selm-(seln)-selp-tst1; CC8: sea-selk-selq, and CC59: seb-selk-selq. Most
isolates with SCCmecVT, ST59, spat437, and dru11 types were pvl
+ (13 isolates), while multidrug resistance ($4
antimicrobials) were associated with SCCmecIII, ST239, spa t037, agrI, and dru14 (119 isolates) (p,0.001). One hundred and
twenty four isolates with the following molecular types had higher VA MIC: SCCmecII and SCCmecIII; ST5, ST239, and ST241;
spa t002, t037, and t421; dru4, dru10, dru12, dru13, and dru14 (p,0.05). No particular molecular types were found to be
associated with MLSBi phenotype.
Conclusions: Four major MRSA clone complexes were found in Taiwan. Further studies are needed to delineate the
evolution of MRSA isolates.
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Introduction
Staphylococcus aureus is one of the most common pathogens in
both community- and hospital-associated infections [1,2,3]. It is
also the leading cause of skin, [4,5], cardiovascular tissue [6] and
osteoarticular tissue [7] infections, pneumonia [5,8], and bacter-
emia [9]. Methicillin-resistant S. aureus (MRSA) has emerged in the
1960s and reached a prevalence of 60–80% in the 1980s [1,10,11].
Patients with invasive MRSA infections have a higher mortality rate
than those with noninvasive MRSA infections [9,11,12]. MRSA is
also the leading cause of death due to microbial infections [4,11].
Several molecular methods have been developed to type MRSA
isolates, including pulsed-field gel electrophoresis (PFGE) [13],
multilocus sequence typing (MLST) [14], and typing based on
polymorphisms of the following genetic loci: the staphylococcal
cassette chromosome mecA (SCCmec) [15], the X region encoding
protein A (spa) [16], the mec-associated hypervariable region (dru)
[17], and the accessory gene regulator (agr) [18]. With these typing
methods, some MRSA isolates including the New York/Japan
(SCCmecII-ST5-agrII), Hungarian (SCCmecIII-ST239-agrI), and
USA 300 (SCCmecIV-ST8-agrI) clones have been identified
worldwide [19,20]. MRSA isolates also harbor a number of
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Valentine leukocidin [23], and exotoxins [19,24].
Although MRSA typing is commonly done, few studies have
been conducted to correlate genotypes with phenotypes. Further-
more, most MRSA typing performed in Taiwan are limited to
isolates from one hospital [25,26,27]. In this study, we expanded
our scope to include MRSA isolates from various locations in
Taiwan. We also correlated molecular types of the MRSA isolates
with their phenotypes based on the virulence factors present in
each isolate.
Materials and Methods
Identification and determination of antimicrobial
susceptibility of MRSA isolates
A total of 1,000 isolates suspected to be MRSA from various
specimens were collected from March to August, 2003 as part of
the Surveillance of Multicenter Antimicrobial Resistance in
Taiwan (SMART) program. Ten hospitals of various medical
centers participated in this program including three each in
northern (hospitals N1, N2, N3), central (hospitals C1, C2, C3),
and southern (hospitals S1, S2, S3) and one in eastern (hospital E1)
part of Taiwan. S. aureus was identified as Gram-positive cocci with
b-hemolysis on 5% sheep blood agar and giving positive results for
catalase, coagulase, DNase, and mannitol fermentation tests.
MRSA isolates were screened with 30-ug cefoxitin disc [28,29] and
confirmed to harbor the mecA gene by polymerase chain reaction
(PCR) [15] and by oxacillin resistance [29]. Among the 1,000
isolates, 157 non-duplicated MRSA isolates from blood samples
from 9 medical centers in Taiwan were used in this study,
including 70 from N1, 4 from N2, 17 from N3, 3 from C1, 1 from
C2, and 18 from C3, 24 from S1, 1 from S3, and 19 from E1
hospitals. Isolates that were resistant to four or more of the
following antibiotics by the disc diffusion test were considered as
multidrug resistance: gentamicin, trimethoprim/sulfamethoxazole
(TMP-SXT), ciprofloxacin, erythromycin, clindamycin, ampicil-
lin/sulbactam, ciprofloxacin, oxacillin, vancomycin, and teicopla-
nin. Inducible macrolide-lincosamide-streptogramin B resistance
(MLSBi) was determined by the D-test, in which the erythromycin
and clindamycin discs were placed 15 mm apart on blood agar
plates [28]. The vancomycin (VA) MICs of the isolates were
determined by both the agar dilution test [28] and the E-test with
strips containing gradients of VA and daptomycin (DAP)
according to manufacturer’s instructions (AB BIODISK, AB
bioMerieux, Sweden).
Bacterial DNA extraction and SCCmec classification
Genomic DNA was extracted from each MRSA isolate using
the Genomic DNA Mini Kit (Geneaid, Taiwan). The genes
encoding the cassette chromosome recombinase (ccr) complex and
the mec complex were typed by multiplex PCR (M-PCR) with 14
primers as described by Kondo et al. [15]. SCCmec types I to V
were identified by comparing the M-PCR banding patterns of the
isolates to those of the following reference strains: ATCC 10442
(SCCmec type I), N315 (SCCmec type II), 85/2082 (SCCmec type
III), MW2 (SCCmec type IVa), WIS (SCCmec type V), and TSGH-
17 (SCCmec type VT). Isolates initially determined to be SCCmecV
were further analyzed with specific primers (ccrC-FR) for
SCCmecVT [30], which was recently renamed as SCCmecVII
(the Taiwan clone) [31].
Multilocus Sequence Typing (MLST)
The following seven housekeeping genes of each MRSA isolate
were amplified and sequenced as described previously [14]: the
carbamate kinase (arcC), shikimate dehydrogenase (aroE), glycerol
kinase (glp), guanylate kinase (gmk), phosphate acetyltransferase
(pta), triosephosphate isomerase (tpi), and acetyl coenzyme A
acetyltransferase (yqiL) genes. The allelic number and profile
(sequence type or ST) of each gene were determined by comparing
the sequences to those of the known alleles deposited in the S.
aureus MLST database (http://saureus.mlst.net/).
Polymorphism of the X region encoding protein A (spa
typing)
The X region of the spa gene contains variable numbers of 21-
to 27-bp repeats, with the 24-bp repeat being most common [16].
The X region of each MRSA isolate was amplified by PCR as
described by Shopsin et al. [32]. The amplified products were
sequenced and analyzed by the Ridom StaphType software
program (version 1.4; Ridom, GmbH, Wurzburg, Germany
[http://spa.ridom.de/index.shtml]), which automatically deter-
mined the repeat profile and the spa type of each isolate [33].
Polymorphism of the mec-associated hypervariable
region
Amplification of the hypervariable region, which contains
variable numbers of 40-bp direct repeat units (dru), was performed
by PCR with primers orf145 and IS431mec as described by Senna
et al. [17]. The copy number of dru in each MRSA isolate was
determined by the size of the amplified fragment according to the
following equation: dru copy no.=(size of PCR product2171)440
[17].
Accessory gene regulator (agr) typing
The agr gene of each MRSA isolate was amplified with primers
Pan, agr1, agr2, agr3, and agr4 as described by Gilot et al [18].
These primers allowed amplification of a 441-bp DNA fragment
from agr group I, a 575-bp fragment from agr group II, a 323-bp
fragment from agr group III, and a 659-bp fragment from agr
group IV strains.
Gene encoding Panton-Valentine leukocidin (pvl)
Amplification of the pvl gene was done with primers luk-PV-1
and luk-PV-2 as described by Lina et al. [23]. The reference strain
TSGH-17 was used as the positive control, and the strain 85/2082
was used as the negative control.
Superantigenic toxin gene profile
Each MRSA isolate was examined for the existence of a total of
18 genes encoding classical (sea, seb, sec, sed, see, seg, seh, sei, selj, selk,
sell, selm, seln, selo, selp, selq, and selr) and newly described
superantigenic (tsst-1) toxins by four multiplex PCRs, with femA
and femB as positive control genes in the M-PCR [34].
Discriminatory power of molecular typing systems and
statistic methods
The discriminatory power of each typing method was
determined by the Simpson’s index of diversity as described by
Hunter [35]. The difference between two consecutive samples
within the same population was determined by the Mann-
Whitney-U test if the population was not normally distributed
(nonparametric), and the difference between two categorical
variables was determined by the Fisher’s exact test. A p value
less than 0.05 was considered significant. The Pearson’s test was
used to determine whether two consecutive samples had a close
(r$0.7) or moderate (0.7.r$0.4) correlation.
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MRSA identification and antimicrobial susceptibility
determination
Antimicrobial susceptibility testing by the disc diffusion method
revealed that 119 (75.8%) of the 157 MRSA isolates were resistant
to multiple drugs including erythromycin (149 isolates, 94.9%),
clindamycin (136 isolates, 86.5%), TMP-SXT (113 isolates,
71.8%), and gentamicin (123 isolates, 78.2%) (Table 1). The
mean vancomycin MIC was determined to be 1.56 mg/L
(range:1–3 mg/L) by the agar dilution method (Table 1); this
value was very close to that determined by the E-test (mean:
1.66 mg/L; range: 1–3 mg/L). The mean daptomycin MIC
determined by the E-test was 0.25 mg/L (range: 0.064–
0.75 mg/L). The Pearson’s coefficient for correlation between
vancomycin and daptomycin resistance showed a moderate
correlation (r=0.47) (Fig. 1).
Molecular typing
There were 5 SCCmec types including types II (9, 5.7%), III (115,
73.2%), IV (21, 13.4%), V (1, 0.6%), and VT (11, 7.0%) (Table 2).
Only two agr groups were found, and most (147, 93.6%) isolates
belonged to agr group I. A total of 7 MLST types were identified,
including ST5 (9, 5.7%), ST239 (99, 63.0%), ST241 (12, 7.6%),
ST59 (27, 17.2%), and others [ST338 (1, 0.6%), ST573 (4, 2.5%),
and ST900 (2,1.3%)].Twonew single locus variants of ST241 were
identified in3 isolates(Table 2).Forspa typing, a totalof14 spatypes
were found; the following 4 types were more prevalent: t037 (107,
68.2%), t437 (20, 12.7%), t002 (8, 5.1%), and t421 (7, 4.5%). There
were 11 dru types determined with dru14 (76, 48.4%), dru9 (23,
14.6%), dru11 (11, 7.0%), dru12 (11, 7.0%), dru4 (10, 6.4%), dru6 (8,
5.1%), and dru10 (7, 4.5%) being more common. The discrimina-
tion indices, defined as Simpson’s diversity index (D value), for
SCCmec, agr, MLST, spa,a n ddru typing were 0.713, 0.232, 0.842,
0.785, and 0.945, respectively.
Table 1. Correlations between molecular types and phenotypes of MRSA blood isolates.
Molecular types Isolate number (percent) Minimal inhibitory concentration (MIC) (mg/L)
Positive
pvl
Positive
D-test
Multidrug
resistance
1
VA
(agar dilution)
VA
(E-test)
DPC
(E-test)
SCCmec II 0(0) 0(0) 7(4.5) 1.61
** 1.57 0.30
*
III 0(0) 12(7.6) 108(68.8)
* 1.66
* 1.74
* 0.28
*
IV 2(1.3) 1(0.6) 3(1.9) 1.24 1.48 0.16
V 0(0) 0(0) 1(0.6) 1.5 2.0 0.19
VT 11(7.0)
* 0(0) 0(0) 1.09 1.36 0.15
agr I 13(8.3) 12(7.6) 114(72.6)
* 1.56 1.67 0.26
II 0(0) 1(0.6) 5(3.2) 1.45 1.60 0.22
MLST ST5 0(0) 0(0) 7(4.5) 1.61
** 1.72
*** 0.31
*
ST239 0(0) 10(6.4) 94(59.9)
* 1.68
* 1.75
* 0.29
*
ST241 0(0) 2(1.3) 10(6.4) 1.42
*** 1.58 0.23
ST59 12(7.6)
* 0(0) 3(1.9) 1.17 1.39 0.15
other 1(0.6) 1(0.6) 5(3.2) 1.55 1.65 0.17
spa t002 0(0) 0(0) 6(3.8) 1.63
** 1.75 0.32
*
t037 0(0) 11(7) 99(63.1)
* 1.65
* 1.72
* 0.28
**
t421 0(0) 1(0.6) 7(4.5) 1.71
** 1.78
** 0.23
***
t437 11(7.0)
* 0(0) 2(1.3) 1.18 1.42 0.15
other 2(1.3) 1(0.6) 5(3.2) 1.30 1.47 0.16
copy no. of dru 4 0(0) 0(0) 8(5.1) 1.60
** 1.70 0.29
*
6 0(0) 2(1.3) 6(3.8) 1.44 1.69 0.24
9 4(2.5) 1(0.6) 5(3.2) 1.22 1.43 0.14
10 0(0) 1(0.6) 5(3.2) 1.50
** 1.64 0.22
**
11 8(5.1)
* 0(0) 3(1.9) 1.36 1.50 0.17
12 1(0.6) 0(0) 9(5.7) 1.59
** 1.73
** 0.23
*
13 0(0) 0(0) 5(3.2) 1.60
*** 1.80
** 0.25
**
14 0(0) 9(5.7) 74(47.1)
* 1.71
* 1.76
* 0.30
*
other 0(0) 0(0) 4(2.5) 1.33 1.42
* 0.21
Total No. (%) (or mean for MIC) 13(8.3) 13(8.3) 119(75.8) 1.56 1.66 0.25
*p,0.05,
**p,0.01,
***p,0.001.
Abbreviations: VA, vancomycin; DPC, daptomycin; pvl, Panton-Valentine leucocidin; agr, accessory gene regulator.
1Multidrug resistance: resistance to $4 classes of antibiotics (disc diffusion test).
doi:10.1371/journal.pone.0030394.t001
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isolates among 9 medical centers in Taiwan was shown in Table
S2. Although it seemed that most identified molecular types were
found equally in four areas of Taiwan, the majority of isolates with
ST59, SCCmecIV and VT, and spa t421 were recovered in N1
hospital. All four ST573 and two ST900 isolates were recovered
from the same hospital (N1) in northern Taiwan (Table S2).
Significant association was noted between various molecular
types (Table S1). For example, SCCmecII isolates were distributed
among agr group II, ST5, spa t002 and dru4 types (p,0.001).
Similarly, SCCmecIII isolates were mostly found in agr group I,
ST239, ST241, spa t037, and dru14 types (p,0.05 for ST241 and
p,0.001 for other corresponding types). SCCmecIV isolates were
mainly seen in agr group II, ST59, ST573, spa t437, and dru9 types
(p,0.05 for agr group II and p,0.001 for other corresponding
types), and SCCmecVT isolates were mostly found in ST59, spa
t437, and dru11 types (p,0.001).
With SCCmec and MLST combination typing, the MRSA
isolates were classified into four clone complexes (CC), including
CC1, CC5, CC8, and CC59 (Table 2). CC1 included SCCmecIV-
ST573 (4 isolates, 2.5%). CC5 contained SCCmecII- ST5 (9
isolates, 5.7%). CC8 (111 isolates, 70.7%) comprised SCCmecIII-
ST239 (99 isolates, 63.1%) or ST241 (12 isolates, 7.6%). CC59 (28
isolates, 17.8%) consisted of SCCmecIV (17 isolates, 10.8%) or VT
(10 isolates, 6.4%)-ST59 (27 isolates, 17.2%) or ST338 (1 isolate,
0.6%) (Table 2). Five isolates did not belong to any of these 4 clone
complexes.
Correlation between molecular types and phenotypes
Thirteen (8.3%) of the 157 MRSA isolates were found to
harbor the pvl gene (Table 1). These isolates were mostly
distributed in SCCmecVT, ST59, spa t437, and dru11 types
(p,0.001). The MLSBi phenotype was also present in 13 isolates
(8.3%), but no significant association between MLSBi and any
specific molecular type was found. The mutidrug resistance (§4
classes of antimicrobials, including oxacillin) phenotype was
significantly correlated with SCCmecIII, agr group I, ST239, spa
t037, and dru14 types (p,0.001). Isolates with higher vancomycin
MIC were noted in SCCmecII and SCCmecIII; ST5, ST239, and
ST241; spa t002, t037, t421; dru4, dru10, dru12, dru13, and dru14
types (p value from ,0.001 to ,0.05 respectively), and those with
elevated daptomycin MIC were found in SCCmecII and
SCCmecIII; ST5 and ST239; spa t002, t037 and t421; dru4,
dru10, dru12, dru13, and dru14 types(p value from ,0.001 to
,0.05 respectively) (Table 1).
The most prevalent toxin genes detected by M-PCR were selk
(134, 85%), selq (133, 85%), sea (105, 67%), and seb (26, 17%).
Some toxin genes were associated with specific molecular types
(Table S3). For example, selk and selq are associated with
SCCmecIII, SCCmecIV, and SCCmecVT; agr group I; ST239; spa
t037 and t3592; and dru 14. The seb gene was mainly found in
isolates with SCCmecIV and SCCmecVT, ST59, spa t437, dru9 and
dru11 types. The tst-1 gene was found to be associated with
SCCmecII; agr group II; ST5; spa t002; and dru4 types (p value from
,0.001 to ,0.05 respectively) (Table S3). A total of 15
superantigenic toxin gene profiles were seen. The most prevalent
Figure 1. Correlation between vancomycin and daptomycin
MICs of 157 MRSA blood isolates determined by E-test; r
(Pearson’s correlation coefficient)=0.474.
doi:10.1371/journal.pone.0030394.g001
Table 2. Clonal complexes and relationship between various
molecular types of 157 MRSA blood isolates.
Clonal
complex (CC) MLST
1
agr
group
SCCmec
type
spa
type No.
CC8 ST239 I III t037 92
t421 4
t138 1
t388 1
t3519 1
ST241 I III t037 9
t421 3
CC5 ST5 I II t002 3
II II t002 5
t242 1
CC59 ST59 I IV t437 11
t1751 2
t3592 3
II IV t084 1
IV T t437 9
t3592 1
ST338 I VT new
4 1
CC1 ST573 I IV t3406 1
II IV t3406 1
t037 1
t3525 1
Others ST900 I III t037 2
new
2 I III t037 2
new
3 I V t037 1
1MLST allelic profile in the order of arcC-aroE-gypF-gmk-pta-tpi-yqiL;
2the alleic profile of 2-3-1-1-new-4-30;
3the alleic profile of 2-3-1-1-4-99-30 after comparing the sequences and allelic
profiles of with those deposited in the S. aureus MLST database (http://saureus.
mlst.net/);
4new spa type (alleic profile: 4-20-17-16- 34) after comparing the sequences and
allelic profiles with those deposited in the spa typing website (http://spa.
ridom.de/index.shtml).
doi:10.1371/journal.pone.0030394.t002
Molecular and Phenotyping Results of Blood MRSA
PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e30394ones were sea-selk-selq (95, 60.5%), seb-selk-selq (17, 10.8%), and selk-
selq (12, 7.6%). One isolate had no detectable toxin gene (Table 3).
Discussion
MRSA strains were originally found in hospital settings (HA-
MRSA) in the 1960s [3,8], but community-associated MRSA (CA-
MRSA) strains have emerged in recent 20 years [36,37]. The
prevalence of MRSA in United States is shown to be increased
from 22.8% to 56.2% during a 11-year surveillance study by the
Center for Disease Control and Prevention [1]. The reports of the
Taiwan Surveillance of Antimicrobial Resistance I and II (TSAR I
and II) in 2000 indicate that 60% of the 400 S. aureus isolates from
65 hospitals in Taiwan were MRSA [10]. The mortality rate of
patients with MRSA bacteremia has been shown to be as high as
33% [9,27]. Because of the great impact of MRSA on patients’
outcome, we investigated the association between genotypes and
phenotypes of MRSA isolates from patients with bacteremia.
Among the 157 independent blood MRSA isolates from 9 medical
centers in Taiwan, 124 (79%) were HA-MRSA (SCCmecII and
SCCmecIII) and 33 isolates (21%) were CA-MRSA (SCCmecIV,
SCCmecV, and SCCmecVT). Most isolates (152, 96.8%) were found
to belong to the following four clonal complexes: CC1, CC5, CC8,
and CC59 (Table 2). The SCCmecIII-ST239 isolates were found to
have a higher rate of multidrug resistance than other isolates, a
finding similar to those of previous reports [5,38]. Interestingly, we
found strains with particular molecular types such as ST573 and
ST900 were exclusively recovered from one university-affiliated
teaching hospital in northern Taiwan (N1), and the ratios of
molecularly CA-MRSA stains (ST59, SCCmecIV and VT, and spa
t421) were higher than those recovered from other hospitals (Table
S2). These findings showed that the molecular types of MRSA
blood isolates were not equally distributed in the island and the
prevalence CA-MRSA might increase in some hospitals, which
was compatible with the previous reports [39,40].
A pandemic MRSA lineage, ST239, has been found to descend
from ST8 and ST30 parents (both belonging to CC8) through
simple chromosome replacement instead of movement of mobile
genetic elements [41]. There is only one allelic difference (arcC)i n
7 housekeeping genes used for MLST between ST8 and ST239,
but they are distinguished at least 6 surface protein-encoding genes
including spa. Recently, Harris et al had delineated the
intercontinental spread and microevolution of the MRSA ST239
isolates by mapping genome-wide single-nucleotide polymor-
phisms (SNPs) to reference sequence [42]. They found MRSA
ST239-spa t037, responsible for the South American clade and
scattering isolates from Europe and Asia, represented the ancestral
ST239 spa type. MRSA ST239-spa t421 was identified as another
clone circulating mainly in Portugal [42]. There were 99 MRSA
isolates in our study classified as ST239, within which 92 isolates
were ST239-spa t037 and 4 were ST239-spa t421. These findings
indicated that those MRSA ST239 strains in Taiwan might be
spread from Europe and America and disseminated islandwide.
Another clone, ST5 accounted for a minority of our MRSA
collection (9 in 157 isolates, 5.7%), and eight of them were
assigned as SCCmecII-spa t002. Nu ˝bel et al investigated the
evolution history of MRSA ST5 clone with SNPs mutation
method and found that limited clades were identified but were not
concordant with results of spa typing [43]. They also found that
geographic spread of MRSA ST5 over a long distance was a rare
event and the progeny of the ST5 resided locally rather than
globally. The haplotype G, consisting of strains from East Asia
including Taiwan, was mainly assigned as SCCmecII-spa t002. Our
study displayed similar molecular typing results of MRSA ST5
strains with the haplotype G reported by Nu ˝bel et al [43].
Based on polymorphisms of the agr gene, we classified our
MRSA isolates into two groups (I and II), and most isolates (147,
93.6%) belonged to agr group I. This finding is consistent with that
of Ho et al. [44] and Lu et al. [45]. Only 10 (6.4%) of our MRSA
isolates belonged to agr group II. Previous studies have shown that
some agr group II isolates are glycopeptide-intermediately resistant
S. aureus (GISA) and hetero-GISA [46,47]. In the study of Moise-
Broder et al., agr group II isolates from 31 of 36 patients with
treatment failure were found to be resistant to vancomycin [21]. In
this study, no significant association was found between agr group
II and vancomycin resistance.
Staphylococcal protein A (SpA) is a cell wall anchored virulence
factor [48]. The polymorphic X region in the spa gene has been
shown to be sufficiently stable for typing with a discriminatory
power comparable to other typing methods including PFGE [16].
A total of 14 spa types were found in this study with types t037,
t437, t002, and t421 being the majority. We also found that most
spa t437 isolates belonged to SCCmecIV, SCCmecVT, and ST59,
similar to the results of a previous studies on CA-MRSA [7,49,50].
In addition, most spa t037 isolates were found to belong to
SCCmecIII and ST239, and those of spa t002 were mostly
SCCmecII and ST5. These results agree with those of HA-MRSA
typing in other studies [7,27,51]. It has been reported that
bacteremic patients in ICU and those with prolonged hospitaliza-
tion were more likely to be infected with MRSA strains with
Table 3. Association of superantigenic toxin gene profiles
with different SCCmec types and agr groups of MRSA blood
isolates.
Superantigenic
toxin gene profiles
SCCmec
type
agr
type No. (%)
None VT I 3 (1.9)
selk-selq III I 12 (7.6)
sed-seg-sei-sell-selm-sel)
n-selo-selp-tst1
II II 1 (0.6)
sec-seg-sell-selm-seln-selo IV I 1 (0.6)
sec-seg-sei-sell-selm-selo IV II 2 (1.3)
sec-seg-sei-sell-selm-selo-selp-tst1 II II 3 (1.9)
sec-seg-sei-sell-selm-selo-selp-tst1 II I 1 (0.6)
sec-seg-sei-sell-selm-seln-selo IV II 1 (0.6)
sec-seg-sei-sell-selm-seln-selo-
selp-tst1
II I 1 (0.6)
sec-seg-sei-sell-selm-seln-selo-selp-tst1 II II 1 (0.6)
sec-seg-sei-sell-selm-seln-selo-selp-tst1 IV I 1 (0.6)
seb-selk-selq IV I 8 (5.1)
seb-selk-selq VT I 8 (5.1)
seb-selk-selq IV II 1 (0.6)
seb-selk-selp-selq IV I 6 (3.8)
seb-sei-selk-selq IV I 2 (1.3)
sea III I 7 (4.5)
sea-selk-selq III I 95 (60.5)
sea-selk-sell V I 1 (0.6)
sea-sec-seg-sei-sell-selm-selo-selp-tst1 IV II 1 (0.6)
sea-seb-selk-selq III I 1 (0.6)
Total 157 (100)
doi:10.1371/journal.pone.0030394.t003
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strains belonged to SCCmecIII-spa t037 [27]. Our study also
showed that SCCmecIII-spa t037 (105 isolates, 66.9%) constituted
most of the MRSA blood isolates with higher vancomycin MICs
than those of CA-MRSA. This may provide a guide in empirical
antibiotic therapy for MRSA bacteremia.
The increased vancomycin MIC of MRSA is a great concern.
Two studies reveal that the success rates of glycopeptide treatment
are decreased in MRSA bacteremic patients if vancomycin MIC
of the MRSA isolate exceeds 1 mg/L [21,22]. Wang et al.
demonstrated that bacteremic patients in ICU and those with
prolonged hospitalization were more likely to be infected with
MRSA strains with elevated vancomycin MIC (2 mg/L), and
those with elevated vancomycin MIC were associated with
increased mortality rate [27]. In this study, vancomycin MICs of
all MRSA blood isolates were found to be equal to or greater than
1 mg/L (range: 1–3 mg/L).
Daptomycin,a cycliclipopeptide,wasapprovedbytheU.S.Food
and Drugs Administration (FDA) for treatment of complicated skin
and soft tissue infections, bacteremia, and endocarditis caused by S.
aureus, including MRSA [52,53]. Cui et al. had reported that
reduced susceptibility of GISA to vancomycin and daptomycin
might result from increased thickness of bacterial wall [54]. We
found that elevated daptomycin MIC was associated with particular
types such as SCCmecII and SCCmecIII; ST5 and ST239; spa t002,
t037 and t421; dru4, dru10, dru12, dru13, and dru14. These isolates
also had elevated vancomycin MICs (Pearson’s correlation
coefficient r=0.47) (Fig. 1). These findings may aid in the selection
of appropriate antibiotic for MRSA and GISA infections.
Clindamycin has been recommended for non-critical infections
caused by S. aureus, including MRSA [37,55]. Resistance to
clindamycin may be constitutive (MLSBc) or inducible (MLSBi) by
erythromycin, and the latter may be misinterpreted as clindamycin
susceptible by the traditional disc diffusion method. We found 13
isolates (8.3%) with the MLSBi phenotype, but they were not
associated with any specific molecular types. The high resistance
rate to erythromycin (94.9%) and clindamycin (86.5%) with low
rate of MLSBi phenotype may represent a high percentage of our
MRSA isolates with the MLSBc phenotype.
Panton-Valentine leukocidin (pvl) is associated with necrotizing
pneumonia [23], scald skin syndrome [56], atopic dermatitis [57],
wounds [56], bacteremia [56], and osteoarticular infections [58].
In this study, 13 MRSA isolates were found to harbor the pvl gene.
Unlike the previous reports by Vandenesch et al. [59] and Udo
et al. [60] in which most pvl+ MRSA isolates belonged to
SCCmecIV, most of our pvl+ MRSA isolates were associated with
SCCmecVT (11 isolates, 84.6%), ST59 (12 isolates, 92.3%), spa
t437 (11 isolates, 84.6%), and dru11 (8 isolates, 61.5%). These
results resembled those of the previous report that the Taiwan
clone (SCCmecVT-ST59-spa t437 or t441-pvl+) with resistance to
erythromycin and tetracycline constituted most of the pvl+ CC59
CA-MRSA strains found in Western Australia [49].
S. aureus produces a number of toxins including staphylococcal
enterotoxins (SEs) and toxic shock syndrome toxin-1 (TSST-1),
which may cause food poisoning, enterocolitis, toxic shock
syndrome, and autoimmune disease in human and livestock
[24,61]. More than 20 different SEs have been found. We found
that HA-MRSA isolates (77% of SCCmecIII and SCCmecII)
harbored more SEs than CA-MRSA (15% of SCCmecIV and 7%
of SCCmecVT). This result is similar to that of Tristan et al. [19]. It
has been shown that each SCCmec type of MRSA contains a certain
type of SE gene. For example, 77% of SCCmecII and 87%
SCCmecIII isolates are sec+, whereas 68% of SCCmecIV and 80% of
SCCmecV isolates are seb+ [26]. We also found that some SE genes
were significantly associated with certain molecular types (for
example, sea, selk, and selq with SCCmecIII-ST59-spa t037; seb with
SCCmecIV or VT-ST59-spa t437; and tst-1 with SCCmecII-ST5-
agrII-spat002).Some isolates harbored multiple toxins, and a total of
15 superantigenic toxin gene profiles were found in our study.
Interestingly, we found that some particular combination of toxin
genes were associated with specific SCCmec types and agr groups
(e.g., sea-selk-selq and selk-selq in SCCmecIII-agrI, seb-selk-selq in
SCCmecIV or VT-agrI, and sec-seg-sei-sell-selm-selp-tst1 in SCCmecII-
agrII). This finding was different from that reported by Becker et al,
in which 429 S. aureus isolates (219 blood isolates and 210 isolates
from anterior nasal nares) from Germany were found to harbor
specific toxic gene combinations such as seg-sei (55% of all isolates
and 53% of blood isolates) as well as sed-sej (7% of all isolates and
10.5% of blood isolates) [62]. These findings indicated that MRSA
blood isolates from Taiwan had unique toxin gene profiles,
suggesting different geographical distribution of MRSA clones.
In conclusion, we have identified four major MRSA clone
complexes CC1, CC5, CC8, and CC59 in Taiwan with the
following molecular types: CC1: SCCmecIV-ST573; CC5: SCCme-
cII- ST5; CC8: SCCmecIII-ST239 or ST241; and CC59:
SCCmecIV or SCCmecVT-ST59 or ST338. The toxin gene profiles
of these MRSA clone complexes are CC1: sec-seg-(sei)-sell-selm-
(seln)-selo; CC5: sec-seg-sei-sell-selm-(seln)-selp-tst1; CC8: sea-selk-selq,
and CC59: seb-selk-selq. In addition, CC1 and CC5 clones had
higher levels of vancomycin MIC than CC59. Continued
surveillance of genotypes and phenotypes of MRSA isolates is
needed to delineate the epidemiologic changes and to provide a
positive impact on clinical practice.
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